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A B S T R A C T
Aims: Calcium phosphate (CaP) particle deposits are found in several inﬂammatory diseases including athero-
sclerosis and osteoarthritis. CaP, and other forms of crystals and particles, can promote inﬂammasome formation
in macrophages leading to caspase-1 activation and secretion of mature interleukin-1β (IL-1β). Given the close
association of small CaP particles with vascular smooth muscle cells (VSMCs) in atherosclerotic ﬁbrous caps, we
aimed to determine if CaP particles aﬀected pro-inﬂammatory signalling in human VSMCs.
Methods and results: Using ELISA to measure IL-1β release from VSMCs, we demonstrated that CaP particles
stimulated IL-1β release from proliferating and senescent human VSMCs, but with substantially greater IL-1β
release from senescent cells; this required caspase-1 activity but not LPS-priming of cells. Potential inﬂamma-
some agonists including ATP, nigericin and monosodium urate crystals did not stimulate IL-1β release from
VSMCs. Western blot analysis demonstrated that CaP particles induced rapid activation of spleen tyrosine kinase
(SYK) (increased phospho-Y525/526). The SYK inhibitor R406 reduced IL-1β release and caspase-1 activation in
CaP particle-treated VSMCs, indicating that SYK activation occurs upstream of and is required for caspase-1
activation. In addition, IL-1β and caspase-1 colocalised in intracellular endosome-like vesicles and we detected
IL-1β in exosomes isolated from VSMC media. Furthermore, CaP particle treatment stimulated exosome secretion
by VSMCs in a SYK-dependent manner, while the exosome-release inhibitor spiroepoxide reduced IL-1β release.
Conclusions: CaP particles stimulate SYK and caspase-1 activation in VSMCs, leading to the release of IL-1β, at
least in part via exosomes. These novel ﬁndings in human VSMCs highlight the pro-inﬂammatory and pro-
calciﬁc potential of microcalciﬁcation.
1. Introduction
Vascular calciﬁcation is a regulated process occurring in aging and
diseased blood vessels that correlates positively with cardiovascular
deaths. The calciﬁc deposits consist of bone-like nanoparticles that
often form aggregates of various sizes and degrees of crystallinity. In
particular, the very small calcium phosphate (CaP) particles that appear
as ‘speckled’ deposits in human atherosclerotic plaques are associated
with plaque instability, increasing the likelihood of plaque rupture and
subsequent thrombus formation [1–3]. Recent studies suggest that
small CaP particles may be damaging due to eﬀects on mechanical
stress in the ﬁbrous cap [4,5], or that CaP particles can be engulfed by
macrophages leading to secretion of pro-inﬂammatory cytokines [6].
Our own studies suggest that small CaP particles are taken up into
vascular smooth muscle cells (VSMCs) via endocytosis, macro-
pinocytosis and plasma membrane damage, causing transient in-
tracellular Ca2+ rises and inducing cell death in subsets of VSMCs [7,8].
Serum proteins, particularly fetuin-A, inhibit cell death by binding CaP
particles and delaying particle uptake, membrane damage and dis-
solution. CaP particles are implicated in the pathogenesis of other dis-
eases including severe calciﬁcation of skin arterioles seen in calciphy-
laxis, degenerative arthritis and breast cancer [9–12]. The association
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of calciﬁcation with inﬂammation in vivo either in joints or in blood
vessels could be explained by several in vitro studies where small
particles of CaP were found to interact with neutrophils, macrophages
and dendritic cells, subsequently activating various signalling me-
chanisms that lead to the release of pro-inﬂammatory cytokines
[6,13–15].
IL-1β has been shown to have a key function in the recruitment of
neutrophils in vivo in response to monosodium urate (MSU) crystals
[16], cholesterol crystals [17] and CaP crystals [18,19]. IL-1β secretion
generally requires a two-step process where cells ﬁrst synthesise pro-IL-
1β, followed by a second stimulus to cleave pro-IL-1β to its active form
by inﬂammasome-activated caspase-1, although other proteases such as
neutral elastase can also cleave pro-IL-1β [20]. The steps involved in
crystal interaction with cells leading to the activation of caspase-1 are
not fully understood, however, SYK activation, intracellular Ca2+ in-
creases, phosphorylation of ASC (apoptosis associated speck-like pro-
tein containing a CARD) and K+ eﬄux have been reported to occur
upstream of caspase-1 activation in various cell types [21,22]. SYK is
most commonly known for its role in coupling immune recognition
receptors bearing cytoplasmic immunoreceptor tyrosine-based activa-
tion motifs (ITAMs) to intracellular signalling pathways but also has
roles in cancer, autophagy and in pro-inﬂammatory responses to cal-
ciﬁed particles in osteoarthritic joints [23–25].
VSMCs reside in the media of blood vessels and their function is to
maintain vascular tone by co-ordinated contraction and dilation.
VSMCs are known to display considerable phenotypic plasticity and
migrate from the medial layer into the intima of diseased blood vessels
where they become proliferative and secrete extracellular matrix that
contributes to the strength of the ﬁbrous cap that overlies the soft
atherosclerotic plaque, protecting it from rupture. In addition to VSMCs
acquiring osteoblast, chondrocyte or adipocyte-like features, VSMCs
secrete several pro-inﬂammatory cytokines constitutively as the cells
age and become senescent [26–29]. Furthermore, VSMCs were recently
shown to diﬀerentiate to a macrophage-like phenotype in a mouse in
vivo model of atherosclerosis [30].
VSMCs are the main cell type within the ﬁbrous cap region that
overlies atherosclerotic plaques, which is thought to form as part of the
healing process and to protect the underlying necrotic core from ex-
posure to the blood vessel lumen. Small particles of CaP at this location
are associated with plaque rupture in man and are thought to reﬂect
active formation of microcalciﬁcation [3,31–35], making the explora-
tion of CaP particle eﬀects on human VSMCs clinically relevant. With
reports that human VSMCs express caspase-1 [36] and that various
forms of crystals can activate caspase-1 in several cell types, we aimed
to determine if CaP particles could inﬂuence human VSMC pro-in-
ﬂammatory mediator production. We identiﬁed a SYK-dependent
pathway in VSMCs leading to caspase-1 activation and release of IL-1β
via exosomes after exposure to CaP particles. Our study highlights the
pro-inﬂammatory potential of human VSMCs in an environment where
cells are exposed to small CaP particles.
2. Methods
2.1. Cell culture
VSMCs were derived from medial layers of normal human aortae
and cultured in smooth muscle basal medium (BM, Lonza) containing
5% foetal bovine serum, insulin, human ﬁbroblast growth factor,
human epidermal growth factor and gentamycin, buﬀered with 3.7 mg/
mL NaHCO3 and 5% CO2. Some of the medial VSMCs used in this study
were kindly provided by Prof. Martin Bennett (Addenbrooke's Hospital,
Cambridge). Donors gave written informed consent for tissue samples
to be used for research, on a standard hospital consent form. Ethical
approval for use of human VSMC cultures was approved by the
Cambridgeshire 1 Research Ethics Committee which conforms to the
principles outlined in the Declaration of Helsinki. In some experiments,
human aortic VSMCs purchased from Lonza or Promocell were used.
Cells from 8 diﬀerent individuals were used in this study; 4 males (aged
22, 28, 30 and 58 years old) and 4 females (aged 35, 43, 51 and
63 years old). Cells were used between passages 6 and 13 and cultured
in BM, unless otherwise indicated.
2.2. Materials
CaP particles were prepared as described previously [8]. Brieﬂy,
aqueous solutions of calcium lactate (9.0 mM; Merck) and diammonium
hydrogen phosphate (5.4 mM; Merck) were adjusted to pH 8.0 with
NaOH and sterile ﬁltered through a Filtropur S plus unit (0.2 μm). The
precipitation reaction was achieved by rapidly pumping (5 mL/min)
both solutions into a glass vessel under sterile conditions. The prepared
suspensions were immediately centrifuged at 900 rpm for 3 min. The
supernatant was removed and the particles were resuspended in 200
times less water volume than the initial nanoparticle dispersion. The
concentration of Ca2+ in the synthesised CaP particles was quantiﬁed
by atomic absorption spectroscopy (AAS; M-Serie, Thermo Electron)
and particle concentrations used in this manuscript are expressed as
mg/mL in terms of Ca2+ content, rather than weight of the nano-
particles. Under the assumption of the stoichiometry of hydroxyapatite
for calcium phosphate, Ca5(PO4)3OH, the content of calcium phosphate
can be computed as w(CaP) = w(Ca2+) M(Ca5(PO4)3OH) / 5 M(Ca)
= w(Ca2+) 2.51. The morphology of freshly prepared nanoparticles
was characterised with scanning electron microscopy (SEM; ESEM
Quanta 400 FEG, gold/palladium sputtering). The particle diameter
was between 30 and 60 nm. The particles had a spherical shape after
the initial synthesis. Nanoparticle preparations were stored in sterile
water at 4 °C and under these conditions, within 2 days the particles
changed their shape (or ‘ripened’, presumably by Ostwald ripening)
from a spherical to a needle-like shape. The particles were not col-
loidally dispersable due to the absence of a surface functionalisation
(i.e. a bare, non-coated surface) and therefore agglomerated. Dynamic
light scattering in pure water is impossible due to agglomeration.
However, we expect a considerable enhancement of the dispersibility in
cell-culture media due to the presence of proteins (formation of a sta-
bilizing protein corona). An image displaying the needle-shaped (ri-
pened) CaP particles interacting with human VSMCs is shown in the
Supplement Fig. S1 and further examples are presented in our previous
studies [8]. The zeta potential of bare calcium phosphate nanoparticles
is slightly negative at neutral pH and will become more negative at
increasing pH (and more positive at decreasing pH). All assays were
performed with particles stored for at least 2 days. Particles were
checked for sterility using an LPS/endotoxin testing kit (stocks of par-
ticles had< 0.5 EU/mL endotoxin, Pierce). Particle solutions were
vortexed immediately prior to addition to cells to achieve a moderate
degree of dispersion.
LPS, nigericin, ATP, and CaCl2 were from Sigma and Na2HPO4 was
from VWR. Z-YVAD-FMK was from BioVision. MSU crystals were from
Adipogen. R406 was from Selleck, and sc-202721 (spiroepoxide in-
hibitor) was from Insight Biotechnology. All chemicals were prepared
and stored following manufacturer recommendations.
2.3. Propidium iodide uptake
An assay using propidium iodide (PI) as a measure of cell death was
used as described previously [8].
2.4. ELISA
Human VSMCs in culture were exposed to various conditions in the
presence or absence of CaP particles and cell supernatants were col-
lected and stored at −20 °C until required for analysis. Samples were
defrosted, centrifuged at 13,000 rpm before measuring human IL-1β
content using a bead-based Alphalisa (Perkin Elmer) or plate-based
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multiplex ELISA (Mesoscale discovery).
2.5. Preparation of cell extracts and Western blotting
Cells were lysed in ice-cold TG lysis buﬀer (Tris-HCl, pH 7.4,
20 mM, Triton X-100, 1% (v/v), Glycerol 10% (v/v), NaCl (137 mM),
EGTA (1 mM) and MgCl2 (1.5 mM), NaF (0.05 M), Na3VO4 (1 mM),
Aprotinin (5 μg/mL) Leupeptin (10 μg/mL) and PMSF (1 mM) and
tested for protein content by BCA assay (Thermo Scientiﬁc). SDS-
loading buﬀer was added to lysates, vortexed and heated at 95 °C for
5 min before centrifugation at 13,000 rpm and fractionation by SDS-
PAGE. Cell supernatants (conditioned medium), were collected on ice
into tubes containing PMSF (ﬁnal concentration 1 mmol/L). SDS-
loading buﬀer was then added and samples were incubated at 95 °C for
5 min before centrifugation at 13,000 rpm and fractionation by SDS-
PAGE. Brieﬂy, SDS-PAGE gels were transferred to Immobilon P mem-
branes (Millipore), which were blocked in 5% (w/v) powdered milk
containing 0.1% (v/v) Tween-20–TBS (tris-buﬀered saline) and probed
with either antibodies recognising pro-IL-1β, SYK (total), phosphory-
lated SYK (Tyr 525/526) (all from Cell Signalling Technologies), IL-1β
(R and D, AF-201), caspase-1 p20 (Adipogen), GAPDH or α-tubulin
(both from ProSci). Mouse anti-human CD63 antibody was from BD
Pharmingen. HRP-conjugated antibodies recognising primary anti-
bodies were purchased from BioRad. Immune complexes were visua-
lised using the ECL system (GE Healthcare or high sensitivity substrate,
Fisher Scientiﬁc). GAPDH or α-tubulin were used as loading controls
and were applied directly to re-probe original blots. In some experi-
ments, Western blot signal intensities were quantiﬁed using ImageJ.
2.6. β-galactosidase staining
VSMCs were cultured in 12-well plates and assessed for β-galacto-
sidase staining following the protocol of Chen et al [37].
2.7. Caspase-1 activity
Cells were treated with or without CaP particles for up to 16 h.
Culture medium was then replaced with a ﬂuorescent caspase-1 in-
hibitor peptide, FAM-YVAD-FLICA, for 1 h at 37 °C following the
manufacturer's recommended protocol (FAM-FLICA caspase-1 assay kit,
ImmunoChemistry Technologies). Cells were then washed and allowed
to incubate for 1 h in basal culture medium to allow non-bound reagent
to elute from cells. Cells were then stained for 5 min with Hoechst
33342 and PI (both 1 μg/mL) before placing in physiological buﬀer [7].
Active caspase-1 was assessed qualitatively in cells cultured in 12-well
plates on a Zeiss Microbeam microscope and images were processed
using ImageJ. Quantitative measurement of active caspase-1 was
achieved using cells cultured in glass-bottomed black 96-well plates
using an IN Cell 6000 high content screening system. Autoﬂuorescence
values for each treatment were corrected by measuring ﬂuorescence in
cells with no FAM-FLICA or no PI. Scatter plots in GraphPad were used
to display levels of active caspase-1 per cell.
2.8. Immunoﬂuorescence
Cells were grown on sterile glass coverslips, treated with CaP par-
ticles and exposed to FAM-YVAD-FLICA as above (section 2.7). After
allowing non-bound reagent to elute for 1 h, cells were ﬁxed in 4%
paraformaldehyde, permeabilised in 0.2% Triton X/PBS, blocked for
1 h in 10% Chemibloc/0.1% Triton X/PBS, washed with 0.1% Triton X/
PBS before incubating with a mouse anti-human IL-β antibody
(0.25 μg/mL, R and D Systems MAB601) for 3 h. Cells were then wa-
shed in 0.1% Triton X/PBS before incubation with anti-mouse IgG
NL557 conjugate (1:200 dilution, R and D Systems NL007), washed
with 0.1% Triton X/PBS followed by a wash with PBS, before ﬁnally
mounting in DAPI-containing hard-set mounting medium (Vectashield).
Cells were imaged using a Nikon A1R confocal microscope and images
were processed using ImageJ.
2.9. Exosome isolation and quantiﬁcation
Quantiﬁcation of exosomes in VSMC conditioned media was per-
formed by using and anti-CD63-coated bead capturing assay, as de-
scribed previously [38]. Brieﬂy, anti-CD63 antibody (BD Bioscience)
was immobilised on 4 μm aldehyde-sulphate latex beads (Invitrogen).
VSMCs were plated on 24-well plates (10,000 cells/well) and incubated
for 16 h. The cells were then washed with EBSS and incubated in M199
supplemented with 2.5% exosome-free FBS, 100 U/mL penicillin,
100 μg/mL streptomycin and 2 mM L-glutamine in the presence or ab-
sence of R406 (1 μM) for 2 h. Media were then replaced with fresh
media with or without the addition of CaP particles (12.5 μg/mL) and
cells were cultured for a further 16 h. Conditioned media were collected
and centrifuged at 2500 x g for 5 min. The supernatants were incubated
with 1 μl of anti-CD63-coated beads on a shaker overnight at 4 °C. Cells
were washed twice in EBSS, trypsinised and quantiﬁed using a Nu-
cleocounter NC-3000 (ChemoMetec A, Denmark). Anti-CD63-coated
beads were washed with blocking buﬀer (PBS containing 2% BSA) and
incubated with CD81-PE antibody (1:50 in blocking buﬀer) for 1 h.
Next, anti-CD63-coated beads were washed with blocking buﬀer and
analysed by ﬂow cytometry (BD Accuri™ C6, BD Biosciences). Arbitrary
units were calculated as (mean ﬂuorescence units x percentage of po-
sitive beads) and normalised to the number of live VSMCs.
Exosomes were puriﬁed from VSMC-conditioned media by diﬀer-
ential centrifugation as previously described [38]. In brief, VSMCs were
incubated in the absence or presence of CaP particles (12.5 μg/mL) in
M199 supplemented with 2.5% exosome-free FBS, 100 U/mL penicillin,
100 μg/mL streptomycin and 2 mM L-glutamine for 16 h. Next, condi-
tioned media were collected and centrifuged for 5 min at 2500 rpm
(Thermo Scientiﬁc Heraeus Multifuge 3SR+ centrifuge, rotor Sorvall
75,006,441 K) and 30 min at 10,000 ×g (Sorvall RC6). Exosomes were
pelleted from the supernatants by ultracentrifugation at 100,000 ×g
for 40 min at 4 °C (Beckman Coulter Optima Max). Exosomes were
washed with PBS, centrifuged again at 100,000 ×g and resuspended in
PBS.
To prepare cell lysates for comparisons with exosome lysates,
VSMCs were washed with PBS and lysed in 0.1 M Tris buﬀer (pH 8.1)
supplemented with 0.15 M NaCl, 1% triton X-100 and protease in-
hibitor cocktail (1:100, Sigma). Cell lysates were sonicated for 5 s
(Branson Soniﬁer 150) and centrifuged at 16,353 ×g for 15 min.
2.10. Statistics
Relevant statistical analyses were performed using GraphPad Prism
and speciﬁc statistical tests are detailed in each of the Figure legends.
For active caspase-1 measurements in live cells, SPSS was used to
perform statistical analysis between cells from diﬀerent individuals.
3. Results
3.1. CaP particles induce IL-1β release from human VSMCs
To establish if CaP particles inﬂuenced IL-1β release from human
VSMCs, cells were exposed to CaP particles for 16 h and IL-1β levels
were measured in cell supernatants. CaP particles stimulated IL-1β re-
lease in the presence or absence of LPS, compared with controls
(Fig. 1A). We conﬁrmed that CaP particles induced release of the ma-
ture form of IL-1β (Supplement Fig. S2A). IL-1β accumulated in con-
ditioned media after exposure to CaP particles (Fig. 1B), while cellular
pro-IL-1β levels did not change after CaP particle exposure (Fig. 1C and
Supplement Figs. S2B and S2C). These data suggest that pro-IL-1β is
constitutively expressed in human VSMCs and that CaP particles sti-
mulated processing and release of IL-1β, rather than stimulating de
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novo IL-1β synthesis. CaP particles also stimulated release of TNFα, IL-
6, IL-8, DPPIV (CD26), GM-CSF and emmprin (CD147) (Supplement
Fig. S3). However, we focussed the present study on the release of IL-1β
from VSMCs.
During the course of this study, it became clear that VSMCs derived
from diﬀerent individuals had variations in levels of IL-1β release
(Fig. 1A and B). Additionally, we observed an increase in basal and CaP
particle-stimulated IL-1β levels as cells matured in culture, i.e. from
early passage (3–5) to mid-passage (6–13) to cells that had undergone
replicative senescence (passage 14–18) (Fig. 2A); senescence was con-
ﬁrmed by β-galactosidase staining (Fig. 2B). No changes in cellular
levels of pro-IL-1β were observed in response to CaP particles or be-
tween proliferating and senescent cells (Fig. 2C, Supplement Fig. S2C
and S2D). Together, these results suggest that (i) CaP particles stimulate
the processing and release of IL-1β from VSMCs and (ii) senescent
VSMCs constitutively release IL-1β and exhibit a greater release of IL-1β
than proliferating VSMCs in response to CaP particles. Thus, variations
observed in IL-1β release from VSMCs were not only donor-dependent
but also due to replicative aging in culture. Nevertheless, addition of
CaP particles increased IL-1β release.
To assess the eﬀects of CaP particles compared with other potential
inﬂammasome activators, VSMCs were incubated with monosodium
urate (MSU) crystals, nigericin or ATP. However, none of these stimu-
lated IL-1β release from VSMCs (Fig. 3 and Supplement Fig. S4). Fur-
thermore, exposing cells to high levels of extracellular Ca2+ or PO43−
did not stimulate IL-1β release (Fig. 3 and Supplement Fig. S4).
3.2. CaP particles induce IL-1β release via caspase-1
Stimulation of IL-1β release from VSMCs by CaP particles was in-
hibited by treatment with the caspase-1 inhibitor YVAD (Fig. 4A). Live
cell imaging of active caspase-1 using a ﬂuorogenic caspase-1 probe
(FAM-YVAD-FLICA) revealed active caspase-1 in a low percentage of
VSMCs after exposure to CaP particles (Fig. 4B, and for quantitative
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Fig. 1. CaP particles stimulate IL-1β release.
A. ELISA measurement of IL-1β release from 6 diﬀerent human VSMC isolates (indicated by 6 diﬀerent symbols) over 16 h with or without CaP particles (12.5 μg/mL) and with or without
a 24-h pre-treatment with LPS (0.1 μg/mL). The control contained equivalent PBS. Values with means are displayed and one-way ANOVA followed by Holm-Sidak's multiple comparisons
test was used to compare groups with the control. Signiﬁcant diﬀerences are indicated as * (P < 0.05) or ** (P < 0.001). B. IL-1β release from 6 diﬀerent human VSMC isolates exposed
to CaP particles (12.5 μg/mL) at time points up to 24 h or LPS (0.1 μg/mL) for 24 h. Values with means are displayed and were analysed by one-way ANOVA followed Holm-Sidak's
multiple comparisons test; signiﬁcant diﬀerences from the no additions ‘0’ control are indicated as * (P < 0.01). C. Western analysis of pro-IL-1β levels in VSMC lysates treated as in B. In
C, blots are representative of 4 independent experiments in cell isolates from diﬀerent individuals. Results from 3 further VSMC isolates are displayed in the Supplement Fig. S2B.
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analysis see Fig. 6D and Supplement Figs. S8 and S9). Active caspase-1
was detected either as a single complex, similar to observations of
single inﬂammasome foci seen in macrophages [39], or in a diﬀuse
pattern. Thus, CaP particles stimulated activation of caspase-1 in a
small proportion of VSMCs.
A minority of VSMCs contained PI after CaP particle exposure, in-
dicating that some cells underwent necrosis (Fig. 4B and for quantita-
tive analysis Supplement Figs. S8 and S9). We therefore tested if con-
ditions that enhanced necrosis aﬀected CaP particle-induced IL-1β
release. In the absence of serum, CaP particles induced higher levels of
necrosis than when serum was present (Fig. 4C), consistent with our
previous studies [7]. However, serum-free conditions did not enhance
the ability of CaP particles to stimulate IL-1β release, despite higher
levels of necrosis (Fig. 4D). These results suggest that necrosis is not the
main mechanism involved in CaP particle-induced IL-1β release and
that serum factors enhance IL-1β release.
We investigated the potential roles of ROS and lysosomal damage in
CaP particle-induced IL-1β release, but found that the ROS scavenger
Trolox and the pan-cathepsin inhibitor e64 had no eﬀect on IL-1β re-
lease (Supplement Fig. S5 and S6).
Using confocal analysis to image active caspase-1 and IL-1β, some
areas of colocalisation were observed within VSMCs (Fig. 5), suggesting
that active caspase-1 and IL-1β interact after CaP particle stimulation.
The colocalisation foci resembled endosomes, both in the perinuclear
area and cell periphery.
3.3. SYK phosphorylation is required for caspase-1 activation and IL-1β
release
Next, we investigated potential signalling mechanisms activated by
CaP particles upstream of caspase-1. We have previously shown by
electron microscopy that CaP particles are rapidly endocytosed by
VSMCs [8]. Inhibitors of endocytosis, wortmannin and chlorpromazine,
reduced IL-1β release, while nystatin and Y27632 did not reduce IL-1β
levels (Fig. 6A). These results suggest that clathrin-mediated en-
docytosis was involved in particle uptake and IL-1β release.
As SYK activation has been linked with crystal-membrane interac-
tions, endocytosis and inﬂammasome activation, we investigated SYK
activation after CaP particle exposure. CaP particle treatment did not
change SYK protein levels but increased phosphorylation at Y525/
Y526, in the SYK activation loop (Fig. 6B and Supplement Fig. S7A and
B). In addition, the SYK inhibitor R406 reduced CaP particle-induced
IL-1β release in a concentration-dependent manner (Fig. 6C). Full in-
hibition of CaP-induced IL-1β release was observed with R406 (1 or
3 μM), and this was the case for each VSMC isolate tested, regardless of
whether cells had low or high levels of basal IL-1β release. Further-
more, R406 inhibited caspase-1 activity after CaP particle exposure, as
assessed by quantitative live cell imaging (Fig. 6D), with no eﬀect on
VSMC death (Supplement Fig. S8 and S9). This suggests that SYK ac-
tivation occurs prior to and is required for caspase-1 activation and
thence IL-1β in response to CaP particles.
Fig. 2. IL-1β release at diﬀerent levels at diﬀerent stages of
VSMC culture.
A. ELISA measurement of IL-1β release from early passage
(3–5), mid-passage (6–13) or senescent VSMCs (14–18)
with or without CaP particles (12.5 μg/mL) incubated over
16 h. Data are displayed on a log-scale and mean levels for
each treatment are indicated. Data were log transformed
prior to statistical analysis. A two-way ANOVA followed by
a Holm-Sidak's multiple comparisons test was used to
compare groups. Signiﬁcant diﬀerences are indicated by *
(P < 0.01) or ** (P < 0.001). 4 diﬀerent VSMC isolates
were used for each cell culture stage. B. β-galactosidase
staining of proliferating (mid-passage) or senescent VSMCs,
showing higher expression in senescent cells. C. Western
analysis of pro-IL-1β levels in proliferating or senescent
VSMC lysates treated with CaP particles (12.5 μg/mL) for
indicated times. Blots showing results from 3 diﬀerent cell
isolates are shown in the Supplement Fig. S2C and S2D.
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3.4. Exosomes as a route for IL-1β release
To assess whether vesicle release may be a mechanism for IL-1β
release from VSMCs, cells were incubated with an exosome release
inhibitor, spiroepoxide [38]. Spiroepoxide reduced CaP particle-in-
duced IL-1β release, suggesting that exosomes are involved in the re-
lease of IL-1β (Fig. 7A). We next measured exosome release from
VSMCs in response to CaP particles and found that CaP particles sti-
mulated exosome release (Fig. 7B). Additionally, the SYK inhibitor
R406 inhibited CaP particle-induced exosome release, suggesting that
SYK phosphorylation is involved in CaP particle-stimulated exosome
release (Fig. 7B).
To conﬁrm if IL-1β is secreted in exosomes, we isolated exosomes
from conditioned media of VSMCs treated with or without CaP parti-
cles. We previously showed that VSMC exosomes are enriched with
tetraspandin CD63 [38] and correspondingly, Western blot analysis
revealed that exosomes enriched with CD63 contained the pro-form of
IL-1β (31 kDa) (Fig. 7C). Notably, CaP particle-treated and control cells
released exosomes with similar levels of IL-1β, which suggests that the
increase in released IL-1β detected by ELISA after CaP particle treat-
ment may be due to increased numbers of released vesicles, rather than
selective loading of released exosomes with IL-1β.
The mature, active, 17 kDa form of IL-1β was not detected in cells or
exosomes but a 28 kDa band was observed in cells in addition to the
31 kDa pro-IL-1β (Fig. 7C, Supplement Fig. S2B). The 28 kDa form of IL-
1β has been reported in other studies as an intermediate form, which is
generated upon the ﬁrst step in caspase-1-mediated cleavage of pro-IL-
1β [40]. Although we found active caspase-1 at foci within cells, in-
dicating intracellular caspase-1 activity, active caspase-1 was also de-
tected in cell supernatants by Western Blotting (Supplement Fig. S10),
suggesting that some IL-1β processing may also occur extracellularly.
4. Discussion
Here we report that CaP particles induce the release of IL-1β from
human VSMCs via activation of SYK and caspase-1. The levels of basal
and CaP particle-stimulated IL-1β release varied between VSMCs iso-
lated from diﬀerent donors and also with stage of cell culture; from
early passage cells, where IL-1β levels were lowest, to cells that had
undergone replicative senescence, where IL-1β levels were highest. This
suggests that senescent VSMCs exposed to CaP particles have the
greatest pro-inﬂammatory potential, compared with proliferating cells,
which is particularly relevant to atherosclerotic plaque caps where
VSMCs that have undergone senescence are thought to weaken plaques
and encourage plaque instability, in aged populations in particular
[41,42]. Why VSMCs are already ‘primed’ to express pro-IL-1β is not
known but may be related to their de-diﬀerentiated, non-contractile
phenotype in culture that is commonly observed in diseased blood
vessels in vivo. Various mechanisms have been proposed for the basal,
unstimulated cytokine release by senescent VSMCs, including altered
signalling pathways and genomic instability [28,29,43,44].
Our studies revealed that human VSMCs do not show enhanced
release of IL-1β in response to several of the common inﬂammasome
agonists reported to activate caspase-1 in macrophages, including ATP,
nigericin and MSU crystals. This suggests that either: (1) human VSMCs
do not share the same upstream inﬂammasome-activating mechanisms
as other cell types (e.g. VSMCs lose purinergic receptor expression in
culture [45]), and that CaP particle composition or physical parameters
such as shape, size and charge may be important in inﬂammasome
activation in VSMCs; or (2) that CaP particles may have additional
stimulatory eﬀects on release mechanisms for IL-1β. Potential dissolu-
tion of the particles being responsible for the eﬀects on IL-1β release
was unlikely, since elevated extracellular levels of either Ca2+ or PO43−
did not mimic the eﬀects of CaP particles. Thus, VSMCs appeared to be
particularly sensitive to CaP particles in terms of stimulating IL-1β re-
lease.
Using live cell imaging, active caspase-1 was detected in a minority
of VSMCs exposed to CaP particles, perhaps reﬂecting transient activity
of caspase-1. Alternatively, since VSMCs are well known to be hetero-
geneous, certain phenotypes within the population of cells may be in-
trinsically primed to activate caspase-1 in response to CaP particles.
Further investigation including phenotyping of cells would help to
elucidate why some VSMCs have higher potential for activating cas-
pase-1. The ﬁnding of high levels of active caspase-1 in subsets of cells
and the assumption that IL-1β is activated within these cells may ex-
plain why we observed relatively low levels of IL-1β release from
VSMCs (mostly in the picomolar range), compared with other cell types
such as macrophages, where agonists activate caspase-1 in almost the
whole cell population, depending on the potency of the stimulus [46].
The diﬀerent primary cell isolates used in the current study were from 8
healthy donors (4 males and 4 females) and in general, we found that
responses to CaP particles were similar between males and females.
However, as we used a relatively small number of donors, this is a
limitation of the study. It would be interesting to investigate if CaP
particles stimulated caspase-1 activation and IL-1β release at higher
levels or in the majority of VSMCs derived from a larger cohort of aged
or diseased blood vessels. A recent study of over 100 individuals
identiﬁed a sub-group of older people with hypertension that had ele-
vated inﬂammasome gene expression proﬁles and constitutive IL-1β
expression [47]. Since calciﬁcation is closely linked with hypertension,
aging and cardiovascular mortality [48], it would be particularly in-
teresting to investigate caspase-1 activation and IL-1β release from
VSMCs derived from hypertensive patients.
Having established that IL-1β was released by VSMCs in response to
CaP particles, we sought to establish which mechanisms control its
release. IL-1β is a leaderless protein and is not secreted by the classical
secretory pathway. Several mechanisms for its release have been pro-
posed including microvesicle shedding from the plasma membrane,
secretion via exosomes, exocytosis of secretory lysosomes, secretion
across the plasma membrane during pyroptotic death, secretory au-
tophagy and passive loss during necrosis [49–51]. Confocal images of
VSMCs suggest IL-1β may be released via vesicle-like structures, most
Fig. 3. Inﬂammasome activators MSU, nigericin (N) and ATP do not induce IL-1β release
from human VSMCs.
ELISA measurement of IL-1β release from 5 diﬀerent VSMCs isolates (indicated by 5
diﬀerent symbols), displayed as fold-change related to ‘0’ control values for each cell
isolate. Cells were treated with either CaP particles (12.5 μg/mL), MSU crystals (12.5 μg/
mL), nigericin (25 μM), ATP (10 mM), CaCl2 (5.4 mM, ‘Ca’), Na2HPO4 (2 mM, ‘P’), vehicle
control (DMSO) or no additions (0) for 16 h. Mean levels for each treatment are indicated.
Raw data are displayed in Supplement Fig. S4. A one-way ANOVA on log-transformed raw
data followed by a Holm-Sidak's multiple comparisons test determined that CaP treatment
signiﬁcantly diﬀered from each of the other treatments (*P < 0.05).
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likely late endosomes/multivesicular bodies, and this concept was
supported by the ﬁnding that inhibition of exosome secretion reduced
CaP particle-induced IL-1β release. It is also possible that necrosis
contributed to the release of IL-1β, since PI positive cells were detected
after 2 h of treatment with CaP particles. However, in serum-free con-
ditions where levels of necrosis were higher than when serum was
present, CaP particle-induced IL-1β levels were found to be lower, ar-
guing against a necrosis-dependent mechanism causing IL-1β loss. The
reason for lower IL-1β release in serum-free conditions could be due to
several mechanisms such as: [1] serum being required for eﬃcient IL-
1β release; [2] because of cell death, fewer cells are available to re-
spond to CaP particles and activate signalling leading to IL-1β release;
or [3] that cells entering quiescence release less IL-1β. However, the
latter possibility is less likely as we observed that highly proliferative
cells from very early passages released the lowest levels of IL-1β. Ad-
ditionally, we found that SYK inhibition reduced caspase-1 activation
but did not reduce numbers of PI-positive cells, suggesting diﬀerent
mechanisms for CaP particle-induced activation of SYK and CaP par-
ticle-induced necrosis. Furthermore, quantitative analysis of PI levels
and caspase-1 levels in VSMCs revealed that cells with high PI (dead
cells) had relatively low levels of active caspase-1, suggesting that
pyroptosis is not involved. However, the kinetics and extent of CaP
particle damage to VSMCs and its relation to SYK activation require
further investigation, especially in regard to studies reporting that slow-
onset necrosis stimulates the NLRP3 inﬂammasome, while rapid ne-
crosis does not [52]. Our results suggest that in an environment with
low serum, CaP particles will induce substantial VSMC death and IL-1β
release, while in a serum-containing environment VSMC death is neg-
ligible, but signalling leading to IL-1β release is greater. In either sce-
nario, inﬂammation is the expected result.
SYK activation is known to be linked with crystal-plasma membrane
interactions and endocytosis, and may have a large range of eﬀects on
downstream signalling such as PI3K and Akt activation [53–56]. We
previously found that CaP particles are taken up by VSMCs via en-
docytosis or macropinocytosis within 5–10 min of exposure to CaP
particles, as demonstrated by electron microscopy [8] and here we
found that inhibition of clathrin-mediated endocytosis reduced the ef-
fects of CaP particles on IL-1β release. This suggested that particle
uptake, rather than membrane surface activation, is important in in-
itiating signalling leading to IL-1β release. However, since endocytosis
inhibitors such as wortmannin can have oﬀ-target eﬀects, further stu-
dies are required to investigate the mechanisms involved in the en-
docytosis of CaP particles and how this might lead to SYK activation.
SYK was activated rapidly in VSMCs, consistent with kinetics of
Fig. 4. CaP particles stimulate caspase-1 activity.
A. ELISA measurement of IL-1β release from 3 diﬀerent VSMC isolates over 16 h with or without CaP particles (12.5 μg/mL) and with or without YVAD (20 μM). A two-way ANOVA
followed by Holm-Sidak's multiple comparisons test was used to determine diﬀerences between means. Results are presented as mean ± SEM, *P < 0.05. B. VSMCs were treated with or
without CaP particles at indicated times then labelled with FAM-YVAD-FLICA (active caspase-1 reagent), PI and Hoechst and imaged live. Arrows indicate foci/cells containing active
caspase-1. Images are representative of 5 experiments in diﬀerent cell isolates, quantitation of active caspase-1 and PI in live cells is displayed in Fig. 6D and Supplement Figs. S8 and S9.
C and D. PI uptake (C) or IL-1β release (D) from 3 diﬀerent VSMCs isolates in serum-free conditions (SFM) or in basal medium containing 5% FBS (BM) with or without CaP particles
(12.5 μg/mL) over 16 h. Mean values± SEM are displayed. In C, a two-way ANOVA followed by Holm-Sidak's multiple comparisons test was performed and signiﬁcant diﬀerences
between corresponding no CaP and CaP-treated samples are indicated by * (P < 0.05). In D, a two-way ANOVA was performed on log-transformed data followed by Holm-Sidak's
multiple comparison's test and signiﬁcant diﬀerences between corresponding no CaP and CaP-treated samples are indicated by * (P < 0.05).
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activation reported in other cell types [57] and the highly selective SYK
inhibitor, R406, inhibited CaP-induced IL-1β release. SYK is involved in
various biological processes including focal plasma membrane damage-
induced necroptosis in red blood cells [58], while overexpression of
SYK in tumor cells leads to senescence [59]. However, it appeared that
in VSMCs, SYK activation, rather than raised SYK protein levels, was
important in IL-1β release. Inhibition of SYK phosphorylation with
R406 also inhibited caspase-1 activation, indicating that SYK phos-
phorylation occurs upstream of caspase-1 and is required for caspase-1
activation. It will be interesting in future studies to investigate the in-
termediate steps that link SYK phosphorylation to caspase-1 activation,
such as other kinases and which inﬂammasome is involved.
We found that the highly selective inhibitor of neutral sphingo-
myelinase, spiroepoxide, which inhibits exosome release, inhibited CaP
particle-induced IL-1β release. Further investigation found that CaP
particles stimulated exosome release, suggested that IL-1β may be ex-
ported from VSMCs via exosomes. Supporting this hypothesis, we found
that R406 inhibited CaP particle-induced exosome release and that
exosomes contained IL-1β. SYK involvement in exosome release has
been suggested by others [60] and raises the possibility that R406 in-
hibits IL-1β release by more than one mechanism, i.e. inhibition of
caspase-1 activation and inhibition of exosome release. We
demonstrated a role for exosomes in IL-1β release but secretion via
other extracellular bodies and/or microvesicles cannot be excluded and
require further investigation. Exosome release is known to be increased
in senescent cells, which may help to explain why higher basal release
of IL-1β was observed in senescent VSMCs. In conditions such as those
found in the environment of the atherosclerotic plaque, exosomes re-
leased from VSMCs have been shown to initiate and propagate miner-
alisation [38]. Thus, a reduction in exosome release by R406 would also
be expected to reduce calciﬁcation, although this remains to be tested
experimentally.
Intriguingly, the mature, active, 17 kDa form of IL-1β was detected
in VSMC supernatants but not in cells or exosomes. The pro-form of IL-
1β (31 kDa) and an additional band at 28 kDa was observed. A lack of
detection of mature IL-1β may have been due to low levels in cells or
exosomes, or perhaps due to rapid release of active IL-1β. The presence
of a 28 kDa form of IL-1β has been described as an intermediate, ﬁrst
step in caspase-1 cleavage [40,61]. Thus, IL-1β was detected in-
tracellularly in VSMCs in a pro- and intermediate cleaved form, in
exosomes in a pro-form, while IL-1β in its pro-, intermediate cleaved
and mature form was detected in cell supernatants. It should be noted
that levels of cleaved forms of IL-1β were low, relative to pro-IL-1β
levels. This observation raises the question of how and where IL-1β is
Fig. 5. Caspase-1 activity colocalises with IL-1β.
VSMCs were treated with or without CaP particles (12.5 μg/mL) for indicated times, labelled with FAM-YVAD-FLICA (active caspase-1 reagent), then ﬁxed and incubated with antibodies
recognising IL-1β. Arrows indicate areas in merged images where active caspase-1 and IL-1β overlap. Arrowheads indicate some cells treated with CaP particles that did not contain IL-1β.
Confocal images are representative of experiments in 3 diﬀerent cell isolates.
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cleaved to generate the mature form. Clearly, the initial step in pro-IL-
1β cleavage was detected within cells and the presence of active cas-
pase-1 within foci in VSMCs suggests intracellular caspase-1 activity.
However, active caspase-1 was also found in cell supernatants, raising
the possibility that some IL-1β processing may occur extracellularly in
VSMC cultures. Although most studies in macrophages describe IL-1β
cleavage by caspase-1 within cells before IL-1β is released, the cleaved
form of caspase-1 is often detected in cell supernatants [56,62] and a
recent study highlighted the detection of extracellular active caspase-1
released from human monocyte/macrophages stimulated with LPS and
ATP [63]. The idea of extracellular processing of pro-IL-1β is not new
and other proteases, such as neutrophil and mast cell-derived proteases
have been implicated in pro-inﬂammatory environments (reviewed in
[61]). This highlights that even if inactive forms of IL-1β are released
by cells, they may be important in generating active IL-1β in vivo.
Additionally, several studies have reported that exosomes were
implicated in the transfer of fully functional cytokines and growth
factors [64–66]. Further studies are required to determine how IL-1β is
packaged and released from VSMCs, and to what extent it is functional.
Mature IL-1β is a potent cytokine known to stimulate neutrophil
migration, cause vascular permeability and induce further calciﬁcation,
all important disease-amplifying mechanisms. Blockade of IL-1β acti-
vation in atherosclerotic plaques is desirable, as reported in a recent
clinical trial that successfully targeted IL-1β and reduced cardiovascular
event rates [67]. The SYK inhibitor used in this study, R406 is the orally
active metabolite of fostamatinib, which is currently in clinical trials for
autoimmune thrombocytopenia, haemolytic anaemia and IgA nephro-
pathy. In previous clinical trials fostamatinib was found to be in-
eﬀective in treating rheumatoid arthritis but it was well tolerated. In a
mouse model of atherosclerosis, fostamatinib was eﬀective in reducing
atherosclerotic lesion size and macrophage inﬁltration [68]. Thus, SYK
inhibition may have therapeutic potential in the vasculature and
Fig. 6. CaP uptake and SYK phosphorylation.
A. ELISA measurement of IL-1β release from VSMCs that were exposed to chlorpromazine (1 μg/mL), wortmannin (100 ng/mL), nystatin (10 μg/mL), Y27632 (10 μM) or vehicle control
(DMSO) for 1 h, then exposed to CaP particles (12.5 μg/mL) for 16 h. A two-way ANOVA followed by Sidak's multiple comparisons test was used to compare groups. Signiﬁcant
diﬀerences are indicated by * (P < 0.01), n = 3, i.e. VSMC isolates from 3 diﬀerent individuals (indicated by 3 diﬀerent symbols). B. VSMCs were treated with or without CaP particles
(12.5 μg/mL) for 10 min and analysed for SYK or phosphorylated SYK (525/526) by Western analysis. Western blots shown are representative of experiments from 3 diﬀerent cell isolates
(see Supplement Fig. S7) Ratios of SYK-P to loading control were higher in CaP-treated cells, compared with non-treated controls (paired t-test of log-transformed data, P < 0.01, n = 3
diﬀerent isolates). C. ELISA measurement of IL-1β release from 5 diﬀerent VSMC isolates exposed to CaP particles (12.5 μg/mL) and R406 at concentrations indicated or vehicle control
(DMSO). One-way ANOVA of log-transformed data was performed followed by Holm-Sidak's multiple comparisons tests; indicated treatments diﬀered signiﬁcantly from control values,
*P < 0.05. D. Quantitation of active caspase-1 in live VSMCs after treatment with CaP particles (12.5 μg/mL) for 0, 2 or 16 h with either a 1 h pre-treatment with R406 (1 μM) or
equivalent DMSO. Results shown are representative of 4 independent experiments in diﬀerent cell isolates. Scatter plots display ﬂuorescence levels of the caspase-1 substrate (FAM-YVAD-
FLICA) for approximately 10,000 live VSMCs for each treatment group. Each dot represents the active caspase-1 level for 1 cell. As indicated, when comparing VSMCs from 4 diﬀerent
individuals, CaP particles increased active caspase-1 activity and this eﬀect was reduced in the presence of R406, when comparing the top 5th percentile of VSMCs at the 16 h time point
(P = 0.0215).
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perhaps also at other locations where CaP particles appear to be da-
maging, such as in osteoarthritis.
In conclusion, our studies in primary human VSMCs suggest that
CaP particles activate SYK and caspase-1 leading to IL-1β release via
exosomes. If similar mechanisms occur in vivo, inhibition of SYK could
potentially interfere with the damaging eﬀects of microcalciﬁcation in
VSMC-rich ﬁbrous caps in addition to other proinﬂammatory targets in
the diseased blood vessel wall. Further work is now required to deci-
pher: how CaP particles activate SYK in VSMCs; exactly how this leads
to caspase-1 activation, exosome and IL-1β release; and to explore the
importance of CaP particle-induced cytokine release in vivo.
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